Navigation Links
Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups
Date:9/2/2010

Long Term Data Presented at ESC 2010 Further Support the Benefit of The... -- STOCKHOLM, September 2, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups

 

STOCKHOLM, September 2, 2010 /PRNewswire/ --

- Additional Analysis of 18 Month Data of the SORT OUT III Trial Provides Detail on Safety and Efficacy Outcomes in Patients With Diabetes, Acute Coronary Syndrome, or Treatment of Multiple Lesions

Three new analyses of subgroups from the SORT OUT III study presented at the European Society of Cardiology (ESC) meeting in Stockholm, Sweden, provide additional detail on longer-term follow-up subgroup safety and efficacy outcomes in the SORT OUT III trial in three high-risk subgroups (diabetes, acute coronary syndrome and multiple lesion). These important data add detail to those already published in the March 2010 issue of The Lancet on the clinical outcomes for the primary endpoint in the total population and in multiple subgroups at 9 months follow-up and on clinical outcomes at 18 month follow up of the randomized comparison of the CYPHER(R) Stent and the Endeavor(R) Stent.

The initial results of the SORT OUT III study were published in the Lancet and showed significantly reduced adverse events at 9 and 18 months for the CYPHER(R) Sirolimus-eluting Coronary Stent over Medtronic's Endeavor(R) Stent in an unselected group of 2,332 patients undergoing coronary intervention in real world clinical practice. The authors reported that subgroup analysis of the primary endpoint of 9-month Major Adverse Cardiac Events (MACE, defined as a composite of cardiac death, myocardial infarction [MI], or target vessel revascularization [TVR]) were also consistent across all subgroups.

The new data from ESC provide important additional information on longer-term outcomes at 18 months in three key groups of patients that are at higher risk of adverse events when undergoing coronary intervention, namely patients with diabetes, acute coronary syndromes, and treatment of multiple lesions. These data confirm that the significant reductions in major adverse events in these subgroups seen at 9 months with the CYPHER Stent compared to the ENDEAVOR Stent were sustained through 18 months of follow-up and provide important details of how the components of MACE (death, MI, and TVR) contribute to the reduction in major adverse events.

Among the high-risk diabetic patient population in SORT OUT III, the incidence of MACE at 18 months was significantly reduced by 74% with CYPHER vs. ENDEAVOR (4.8% in the CYPHER Stent group vs. 18.3% in the Endeavor(R) Stent group; hazard ratio 4.05; 95% confidence intervals: 1.86-8.82). This difference was driven by statistically significant reductions in death, MI, TVR and TLR favoring the CYPHER Stent. In the CYPHER Stent group, the incidence of MACE was also significantly reduced by 46% compared to the ENDEAVOR Stent in patients without diabetes (4.5% in the CYPHER Stent group vs. 8.3% in the ENDEAVOR Stent group; hazard ratio 1.87, 95% confidence intervals: 1.30-2.69).

Among patients with acute coronary syndrome in SORT OUT III (defined as patients with unstable angina or myocardial infarction), the incidence of MACE at 18 months was significantly reduced by 43% with CYPHER vs. ENDEAVOR (5.0% in the CYPHER Stent group vs. 8.7% in the Endeavor(R) Stent group; hazard ratio 1.78; 95% confidence intervals: 1.10-2.88). This difference was driven by a statistically significant reduction in TLR and TVR favoring the CYPHER stent. In the CYPHER Stent group the incidence of MACE was also significantly reduced by 60% compared to the ENDEAVOR Stent in patients with stable angina (4.2% in the CYPHER Stent group vs. 10.4% in the ENDEAVOR Stent group; hazard ratio 2.53, 95% confidence intervals: 1.60-4.02).

Finally, among the high-risk group treated for disease in multiple lesions in SORT OUT III, the incidence of MACE at 18 months was significantly reduced by 80% with CYPHER vs. ENDEAVOR (2.6% in the CYPHER Stent group vs. 13.2% in the Endeavor(R) Stent group; hazard ratio 5.29; 95% confidence intervals: 2.59-10.8). This difference was driven by statistically significant reductions in death, MI, and TVR favoring the CYPHER Stent. In the CYPHER Stent group the incidence of MACE was also significantly reduced by 35% compared to the ENDEAVOR Stent in patients treated for disease in one lesion (5.4% in the CYPHER Stent group vs. 8.3% in the ENDEAVOR Stent group; hazard ratio 1.55, 95% confidence intervals: 1.06-2.27).

"The SORT OUT III subgroup analyses further support significant safety and efficacy differences between the CYPHER(R) Stent and the Endeavor(R) Stent," said Campbell Rogers, M.D., Chief Scientific Officer and Head, Global Research and Development, Cordis Corporation and concludes, "In these data sets, risks of adverse events are up to five-fold higher with the Endeavor(R) Stent than with the CYPHER(R) Stent in patients with other complications like diabetes that are described in these data."

Notes to Editors:

About CYPHER(R) Stent

The CYPHER(R) Stent has been chosen by cardiologists worldwide to treat approximately three million patients with coronary artery disease. The safety and efficacy of the device is supported by a robust clinical trial program that includes more than 70 studies that examine the performance of the CYPHER(R) Stent in a broad range of patients.

About Cordis Corporation

For more than 50 years, Cordis Corporation, a Johnson & Johnson company, has been a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease.

*Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). Rapamune is a trademark of Wyeth Pharmaceuticals.

**The third party trademarks used herein are trademarks of their respective owners.


'/>"/>
SOURCE Cordis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010
2. Resverlogix Scientific Data Presented at EAS Congress
3. Very Small Embryonic-Like Stem Cell Mobilization Data Presented at International Society for Stem Cell Research Annual Meeting
4. Delcath Highlights Phase III Trial Results Presented at ASCO
5. Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
6. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
7. Two-Year Follow up Data of NuBac® IDE Feasibility Study Was Presented at SAS Meeting
8. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
9. Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
10. Zymes LLC, University of Windsor and National Research Council of Canada Collaborative Research Presented at the 2010 Experimental Biology Meeting in Anaheim, California
11. Gramene Announces Scholarships for Groups Underrepresented in Science to Learn How to Use Bioinformatics and Genomics Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... SAN DIEGO and SAN FRANCISCO ... , a privately-held regenerative medicine company, and Beyond Type ... living with type 1 diabetes, today announced a grant ... develop a functional cure for type 1 and other ... decade, ViaCyte has been developing innovative stem cell-derived cell ...
(Date:2/22/2017)... Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on ... companion animals, will host a live conference call on Tuesday, ... results from the fourth quarter and full year ended December ... access the audio webcast or use the conference ... ...
(Date:2/22/2017)... ... ... Park Systems , a leader in Atomic Force Microscopy (AFM) since ... attendees and Park customers on Feb. 27, 2017 from 12-2pm at Morton’s The Steakhouse ... The luncheon will feature a talk on Automated AFM for Small-Scale and Large-Scale Surface ...
(Date:2/22/2017)... 2017 Scientists propose in Nature ... in Gaucher and maybe other lysosomal storage diseases as ... than current therapies. An international research team ... which also included investigators from the University of Lübeck ... Feb. 22. The study was conducted in mouse models ...
Breaking Biology Technology:
(Date:2/22/2017)... Feb. 22, 2017 With the biometrics ... Research identifies four technologies that innovative and agile ... significant share in the changing competitive landscape: multifactor ... authentication.   "Companies can no longer ... security," says Dimitrios Pavlakis , Industry Analyst ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... today reported financial results for its quarter and year ended ... quarter of 2016 was $3.9 million compared to $6.9 million ... fourth quarter of 2016 was $0.6 million compared to $2.6 ... the fourth quarter of 2016 was $0.5 million, or $0.02 ...
Breaking Biology News(10 mins):